

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4670513

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the PATENT NUMBER FROM 13/899,445 TO 9,089,559 previously recorded on Reel 043999 Frame 0749. Assignor(s) hereby confirms the ASSIGNMENT. DOCUMENT ID NO.504563666.
CONVEYING PARTY DATA	
Name	Execution Date
ONXEO S.A.	09/08/2017
RECEIVING PARTY DATA	
Name:	MONOPAR THERAPEUTICS INC.
Street Address:	5 REVERE DR., SUITE 200
City:	NORTHBROOK
State/Country:	ILLINOIS
Postal Code:	60062
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	13119229
Patent Number:	9089559
Patent Number:	9192599
CORRESPONDENCE DATA	
Fax Number:	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	anagelberg@marshallip.com
Correspondent Name:	MARSHALL, GERSTEIN & BORUN LLP
Address Line 1:	233 SOUTH WACKER DRIVE
Address Line 2:	SUITE 6300
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	32591/G1000
NAME OF SUBMITTER:	AUDREY NAGELBERG
SIGNATURE:	/Audrey Nagelberg/
DATE SIGNED:	11/02/2017
Total Attachments: 8	
source=Monopar Assignment2#page1.tif	

source=Monopar Assignment2#page2.tif
source=Monopar Assignment2#page3.tif
source=Monopar Assignment2#page4.tif
source=Monopar Assignment2#page5.tif
source=Monopar Assignment2#page6.tif
source=Monopar Assignment2#page7.tif
source=Monopar Assignment2#page8.tif

ASSIGNMENT OF PATENT RIGHTS

This assignment agreement ("Assignment") effective as of September 8, 2017 ("Effective Date"), is entered into by and between **Onxeo S.A.**, a French société anonyme à Conseil d'administration duly organized and existing under the laws of France, with a corporate address of 49, boulevard du Général Martial Valin, 75015 Paris, France ("**Assignor**"), and **Monopar Therapeutics Inc.**, a corporation duly organized and existing under the laws of the State of Delaware, with a corporate address of 5 Revere Dr., Suite 200, Northbrook, Illinois 60062, United States of America ("**Assignee**").

WHEREAS, the parties entered into that certain Option and License Agreement dated June 17, 2016 ("**License Agreement**") pursuant to which Assignor agreed to assign Licensed Patents (as defined in the License Agreement) to Assignee.

NOW, THEREFORE, in consideration of the foregoing and \$1.00 (One U.S. Dollar) and other good and valuable consideration, the receipt and sufficiency of which are hereby agreed, Assignor hereby assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, subject to the terms and conditions of the License Agreement, in the patents and patent applications listed in the attached Schedule A, and to the inventions described therein and improvements thereof, including applications claiming priority thereto, all continuations and divisionals of said patents, and, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof, including the right to claim priority benefit of or to said patent applications and to bring suit and to claim and retain all damages and/or seek other remedies for the past, present and future infringement of any of the foregoing and request the Commissioner for Patents in the United States and similar authorities outside the United States to issue said patents to and in the name of the Assignee (collectively the "**Patent Rights**").

Except in favor of Assignee, Assignor represents and warrants that is it the owner of the Patent Rights herein assigned, that Assignor has the right to make this Assignment, that the undersigned has the authority to bind Assignor and act on Assignor's behalf, and that there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the Patent Rights herein assigned.

Upon the request of Assignee, the Assignor agrees to execute any and all documents and take actions reasonably requested to effectuate this assignment and Assignee's rights in the Patent Rights, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective authorized signatories below.

Page 1 of 4



Onxeo S.A.



Monopar Therapeutics Inc.

The parties execute and deliver this Assignment by their respective authorized signatories below.

ASSIGNOR: Onxeo S.A.

Date September 8th 2017

[Signature]
Name: P. H. H. H. H.
Title: EVP. Corp. Dev. & US Operations
Place:

C. DENG
Witness Name:

Date 08 SEPT 2017

A. SIMON
Witness Name:

Date 08 SEPT 2017

ASSIGNEE: Monopar Therapeutics Inc.

Date September 14, 2017


Ch. D. Robi
Name: Chandler D. Robinson
Title: CEO
Place: EVANSTON, IL USA

Casey Bloomer
Witness Name: Casey Bloomer

Date 09/14/2017

[Signature]
Witness Name: Satima Rajan

Date 09-14-17



Page 2 of 4

P.H.
Onxeo S.A.

Ch. D. Robi
Monopar Therapeutics Inc.

ACCEPTANCE OF ASSIGNMENT

We the undersigned, **Monopar Therapeutics Inc.**, do hereby declare that we accept from **Onxeo S.A.**, the assignment of the Patent Rights as set forth in the above assignment.


On behalf of Assignee,


Chandler D. Robinson
Name
CEO
Title

hereby confirms Assignee's acceptance.

Ch D. Kali September 14, 2017
Signature Date

Page 3 of 4


Onxeo S.A.


Monopar Therapeutics Inc.

Schedule A

Onxeo reference	Country/Region	Application Number	Grant Date	Patent Number	Status
PAT-102 (WO2010/031819)	Europe (Priority)	08164648.1	/	/	Withdrawn
	Europe (AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IT, NL, NO, PL, RO, SE, SK, TR)	9723131.7	10/02/2016	2395997	Granted
	United States	13/119,229	/	/	Abandoned
	United States (Cont)	13/899,445	28/7/2015	9,089,559	Granted
	United States (Cont)	14/612,143	24/11/2015	9,192,599	Granted
	Canada	2,732,893	14/3/2017	2,732,893	Granted
	China	200980136551.8	27/8/2014	102170877	Granted
	Hong-Kong	11114048	12/8/2016	1159494	Granted
	Israel	210916	29/9/2016	210916	Granted
	India	2032/DELNP/2011	/	/	Abandoned
	Japan	2011-527323	1/4/2015	5693455	Granted
	Japan (Divisional)	2014-186880	/	/	Abandoned
	Korea	2011-7006531	17/2/2014	10-1352210	Granted
	Singapore	201100613-7	30/09/2013	165671	Granted
	Australia	2009294612	20/08/2015	2009294612	Granted
	South Africa	2011/1175	26/10/2011	2011/1175	Granted

Onxeo reference	Country/Region	Application Number	Grant Date	Patent Number	Status
PAT-268 (WO2016/165775)	International	PCT/EP2015/058419	/	/	Pending
PAT-269 (WO2016/180834)	Europe (Priority)	15303723.6	/	/	Withdrawn after the PCT filing
	International	PCT/EP2016/060466	/	/	Pending

Page 4 of 4


Onxeo S.A.


Monopar Therapeutics Inc.